Lupin Receives Approval For Leflunomide Tablets USP

Pharma major Lupin Limited (Lupin) has received approval for its Leflunomide Tablets USP, 10 mg and 20 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Arava® Tablets, 10 mg and 20 mg, of SanofiAventis. The product would be manufactured at Lupin’s Pithampur (Unit 1) facility, India.

Leflunomide Tablets USP, 10 mg and 20 mg, are indicated for the treatment of adults with active rheumatoid arthritis (RA).

Leflunomide Tablets USP (RLD: Arava ® Tablets) had an annual sales of approximately USD 44 million in the U.S. (IQVIA MAT December 2019).

Shares of LUPIN LTD. was last trading in BSE at Rs.724 as compared to the previous close of Rs. 721.35. The total number of shares traded during the day was 28840 in over 1839 trades.

The stock hit an intraday high of Rs. 726.55 and intraday low of 716.1. The net turnover during the day was Rs. 20826094.-Equity Bulls